ADDC, AstraZeneca partner for drug development in academic research
The Academic Drug Discovery Consortium (ADDC) has formed a collaboration with AstraZenecaaimed at facilitating efforts by researchers from academia and institutions toward the discovery of novel compounds with potential pharmaceutical application. More specifically, the goal of this partnership is to provide ADDC members with access to a high-quality compound library, while allowing AZ the opportunity to collaborate with academic researchers to identify novel disease targets and drugs across a wide range of therapy areas.
The institutions selected to participate in this project will receive access to up to 250,000 compounds from AZ's internal screening library. The compounds to be made available in this project are intended to provide a broad representation of AZ's compound collection.
In order to be considered for this project, candidate institutions must be members of ADDC and respond through a Request for Proposals (RFP) process. Responses will be judged by a Technical Review Committee that will be comprised of representatives from ADDC and AZ. It is expected that this process will initiate five projects per year for three years, with an option to be renewed.